SolidSense Assay™

Assay Guided Personalized Solid Tumor Therapy

Treating solid tumors can be very challenging even though there are endless anti-cancer drugs in clinical use.

QantaScope developed an advanced diagnostic technology where cancer cells are labelled with a specific OmniFluorBright™ (OFB) stain. As a result of this unique SolidSense Assay™ technology, drug sensitivity screening on solid tumors can be performed. Depending on the tumor size a number of anti-cancer drugs can be sensitivity tested on fresh tumor sections originating directly from the cancer patient.

As a part of the collaboration project, oncologists - treating patients with advanced cancer types where therapy protocols are not available or already has been exhausted - are welcome to contact us.

SolidSense Assay™ can also be of interest for pharmaceutical companies during their clinical trial stage for testing solid tumors drug sensitivity and preselect trial patients.

SolidSense Assay™ is only available as collaborative project.

[1]

 Clinical.Study@qantascope.com [2]